NCT03455842 - The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

December 31, 2018

Study Completion Date

October 22, 2019

Conditions

Seropositive RA

Interventions

BIOLOGICAL

BCD-089, 162 mg, s/c, qw

Subcutaneous injections of anti-IL6R every week

BIOLOGICAL

BCD-089, 162 mg, s/c, q2w

Subcutaneous injections of anti-IL6R every other week

DRUG

placebo

Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week

Trial Locations (4)

1st City Clinical Hospital, Minsk

Chelyabinsk Regional Clinical hospital, Chelyabinsk

Kazan State Medical University, Kazan'

North-Western State Medical University n.a. I.I.Mechnikov, Saint Petersburg